Morgan Stanley’s $60 target on CRSP

CRSP Crispr Therapeutics AG

$48.4 → $60 (+24%) by Jul 2027

Equal Weight · raises · said Jul 30, 2026 · 12-month default horizon

Open: judged on the close on Jul 30, 2027

The article this target came from

Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy?

Yahoo Finance · Jul 30, 2026

Terence Flynn, a Morgan Stanley (NYSE: MS) analyst, recently raised his CRISPR Therapeutics price target to $60, up from $33, and upgraded his rating to 'hold.'

Morgan Stanley’s track record → Crispr Therapeutics AG →

A fact about what Morgan Stanley published, as reported by Yahoo Finance, not a recommendation from Dalsna Finance; Morgan Stanley is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.